Literature DB >> 9829026

Out-patient, multi-modal behaviour therapy for obsessive-compulsive disorder.

I Hand1.   

Abstract

BACKGROUND: With regard to long-term outcome, behaviour therapy is the first choice treatment for obsessive-compulsive disorder (OCD), with or without concomitant selective serotonin reuptake inhibitor (SSRI) medication. Yet, results from research trials, usually restricted to exposure with response-preventions and other symptom-directed techniques, may not be generalisable to people with OCD in community health care services.
METHOD: For more than 20 years we have delivered out-patient behaviour therapy to unselected people with OCD from the community, including those with motivational and compliance problems. Prospective-retrospective follow-ups were carried out from 1-13 years after treatment.
RESULTS: This paper describes the applied multi-modal, strategic-systemic behaviour therapy, and our partially new model of OCD. Compliant patients achieved the usual success rate of 65-70%, but this drops to 50% if all patients treated are included in the analysis.
CONCLUSIONS: For major subgroups of OCD, behavior therapy is a very effective treatment modality. Exposure is essential, but additional ('causal') interventions are equally important in about half of the patients from unselected samples. Both behaviour therapy and drug-treatments need to be improved and predictive variables for outcome of either of them are urgently needed.

Entities:  

Mesh:

Year:  1998        PMID: 9829026

Source DB:  PubMed          Journal:  Br J Psychiatry Suppl        ISSN: 0960-5371


  2 in total

1.  Obsessive-Compulsive Disorder and Tourette's Syndrome.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-03       Impact factor: 3.972

2.  How to treat the untreated: effectiveness of a self-help metacognitive training program (myMCT) for obsessive-compulsive disorder.

Authors:  Steffen Moritz; Lena Jelinek; Marit Hauschildt; Dieter Naber
Journal:  Dialogues Clin Neurosci       Date:  2010       Impact factor: 5.986

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.